ALPS Medical Breakthroughs ETF
$51.64−2.21 (−4.10%)
- 0.50%
- $187M
- +31.0%
- 0.00%
- 0M sh
- $53.79
- low $40.57high $70.85
The ETF.net SBIO Grade
C
Score 46 out of 100
- 9 of 17
Score 46 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.D38 out of 100Rank 10 of 17Mission
Whether the fund did what it promised, tested against its stated mandate.Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.D29 out of 100Rank 14 of 17Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.B55 out of 100Rank 7 of 17Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.A82 out of 100Rank 4 of 17Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.B55 out of 100Rank 9 of 17
Our read on SBIO
CSBIO goes at biotech through a purpose-built medical breakthroughs index instead of the household benchmarks, spreading roughly 100 drug developers across one basket. A specialist route, priced at the category's middle.
The fund seeks investment results that generally track, before fees and expenses, the performance of the S-Network Medical Breakthroughs Index (PMBI).
Why people hold it
- Tracks the S-Network Medical Breakthroughs Index, a dedicated rules-based basket rather than the standard biotech benchmarks most funds in the group follow.
- Roughly 100 holdings, so no single drug readout carries the whole fund.
- The 0.50% expense ratio sits right at the median for biotech and genomics funds. No premium charged for the narrower mandate.
- Trading since 2014, giving it a decade-plus of live operating history through several biotech cycles.
Worth knowing
- Thinly traded next to the giants of the category, so spreads and limit orders matter more here than with the household names.
- Several funds in the same biotech cohort screen stronger overall, and some cost less: IBBQ at 0.19% and XBI at 0.35% versus SBIO's 0.50%.
- Not an income vehicle. Whatever this fund does, it does through the share prices of the drug developers it holds.
SBIO Holdings
- Stocks
- 104
- 31%
- CGON
Sectors
- Health Care100.0%
Geography
- United States88.94%
- Canada2.38%
- United Kingdom2.24%
- China1.92%
- Netherlands1.78%
- Belgium1.64%
- Germany0.75%
- Switzerland0.35%
SBIO Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
SBIO$13,102
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | SBIO |
|---|---|
| Year to date | +5.1% |
| 1 month | −14.9% |
| 3 months | −19.9% |
| 1 year | +31.0% |
| 3 years | +30.6% |
| 5 years | +4.0% |
| 10 years | +9.3% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | SBIO |
|---|---|---|
| 2026 YTD | +5.1% | |
| 2025 | +55.1% | |
| 2024 | +3.8% | |
| 2023 | +8.7% | |
| 2022 | −28.1% | |
| 2021 | −17.5% | |
| 2020 | +21.2% |
SBIO in the news
SBIO Dividends
- 0.00%
No distributions in the last 12 months.
Distribution history
SBIO Risk
- 28.7%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.92
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −52.5%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.95
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
SBIO Cost
0.50%
SBIO0.50%
- The middle half of Biotech & Genomics funds
- Median 0.47%
9 of the 17 Biotech & Genomics funds charge less.
Other funds in Biotech & Genomics
- BIDNAiShares Genomics Immunology and Healthcare ETFExpense ratio 0.47%1 year return +74.8%
- BPBEInvesco Biotechnology & Genome ETFExpense ratio 0.59%1 year return +39.2%
- CIBRNiShares Neuroscience and Healthcare ETFExpense ratio 0.47%1 year return +15.3%
- CGNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETFExpense ratio 0.35%1 year return —
- CGNOMGlobal X - Genomics & Biotechnology ETFExpense ratio 0.50%1 year return +64.9%